The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

开始日期2025-01-15

申办/合作机构

St. Olavs Hospital HF

[+9]

NCT06698887

/ RecruitingN/A

Long-Term Safety Follow-Up Surveillance for Phase 3 Trial (KarMMA-9/CA089-1043) to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.

开始日期2024-09-11

申办/合作机构

Bristol Myers Squibb Co.

100 项与艾基维仑赛相关的临床结果

登录后查看更多信息

100 项与艾基维仑赛相关的转化医学

登录后查看更多信息

100 项与艾基维仑赛相关的专利（医药）

登录后查看更多信息

201

项与艾基维仑赛相关的文献（医药）

2026-03-01·Transplantation and Cellular Therapy

Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study

Article

作者: Irfan, Sohaib ; Kamboj, Ishita ; Rahman, Raeef ; Qureshi, Raabia ; Ahmed, Nausheen ; Abdallah, Al-Ola ; Lutfi, Forat ; Ayoobkhan, Fathima Shehnaz ; Mahmoudjafari, Zahra ; McGuirk, Joseph ; Vojjala, Nikhil

Chimeric antigen receptor T-cell therapy (CAR-T) and T-cell engager antibody (TCE) revolutionized relapsed refractory multiple myeloma (RRMM), non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia (ALL) treatment. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a potentially fatal rare complication characterized by cytopenia, coagulopathy, transaminasemia, and hyperferritinemia. We aim to analyze the IEC-HS reported cases, patterns, and outcomes in RRMM and NHL patients undergoing CAR-T and TCE therapy utilizing the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. We conducted a retrospective postmarketing pharmacovigilance inquiry using the FAERS database and the Medical Dictionary for Regulatory Activities (MEDRA). The database was accessed on March 20, 2025 to examine the adverse effects of CAR-T: idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel), and TCE (teclistamab, elranatamab, talquetamab, mosunetuzumab, glofitamab, and epcoritamab) since their FDA approval in the United States and non-US populations. Descriptive analysis was used to describe reported proportions and outcomes. Reported mortality per product was calculated for patients with IEC-HS. Cases reported in 2024, were used to calculate reporting odds ratio (ROR) and empirical Bayesian geometric mean (EBGM) to compare the drugs for IECHS events reported. A total of 23,315 unique case safety reports (ICSRs) were analyzed, identifying 378 (1.62%) reports of IEC-HS. Reported mortality was high among these patients (n = 232/378, 61.3%). A formal disproportionality analysis, limited to 2024 reports to ensure a contemporary comparison, was performed. Tisa-cel (ROR 2.20) and cilta-cel (ROR 2.24) both demonstrated statistically significant disproportionate reporting signals for IEC-HS. In contrast, axi-cel, which accounted for the highest absolute number of reports (n = 114/378), did not show a significant signal in this analysis (ROR 1.02), suggesting its high case volume is proportional to its high overall reporting frequency. Teclistamab showed a significantly reduced likelihood of HLH reporting (ROR 0.43). IEC-HS is a rare but potentially fatal complication. Our disproportionality analysis identifies significant reporting signals for tisa-cel and cilta-cel. The high absolute number of cases observed for products like axi-cel appears to reflect high utilization rather than a disproportionate risk, underscoring the necessity of using statistical signal detection methods when interpreting spontaneous reports.

2026-03-01·Transplantation and Cellular Therapy

Impact of Intensive Cyclophosphamide-containing multi-agent Bridging Therapy on Outcomes After Idecabtagene Vicleucel in Multiple Myeloma

Article

作者: Matsumoto, Chiaki ; Sato, Kota ; Hosoya, Osamu ; Kikuchi, Taku ; Sugita, Shotaro ; Kunisada, Kodai ; Tsukada, Nobuhiro ; Kondo, Ukyo ; Ishida, Tadao ; Abe, Yu ; Takei, Tomomi ; Watanabe, Miyu ; Nomura-Yogo, Moe

BACKGROUND:

Bridging therapy (BT) is frequently required during manufacturing of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy in relapsed/refractory multiple myeloma. In patients with aggressive disease, intensive cyclophosphamide-containing multi-agent chemotherapy may be selected; however, its post-CAR-T impact remains uncertain, partly due to potential confounding by indication.

OBJECTIVE:

To evaluate the impact of intensive cyclophosphamide-containing multi-agent BT on clinical outcomes after idecabtagene vicleucel infusion in a real-world setting.

STUDY DESIGN:

We conducted a retrospective single-center cohort study of patients with RRMM who received ide-cel between November 2022 and December 2025. Intensive BT was defined as VTD-PACE or DCEP (cyclophosphamide-containing multi-agent chemotherapy) and analyzed by the number of cycles (0/1/2). PFS was estimated using Kaplan-Meier methods and compared with log-rank tests; multivariable Cox models were used to adjust for baseline disease aggressiveness. Hematologic recovery and grade ≥3 infections were evaluated using cumulative incidence methods with competing risks. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded per the American Society for Transplantation and Cellular Therapy consensus grading.

RESULTS:

Among 94 patients (median follow-up, 12.5 months by the reverse Kaplan-Meier methods), patients receiving intensive BT more frequently had aggressive disease at leukapheresis. The overall response rate (≥partial response) to BT was 75.5% and did not differ by cycle group (p = 0.32). Median PFS differed by cycle group in univariable analysis (p = 0.045), but intensive BT was not independently associated with inferior PFS after adjustment (hazard ratio [HR] 1.68, 95% confidence interval [CI] 0.45-6.24; p = 0.44). The second revision of International Staging System assessed at the time of leukapheresis remained independently associated with PFS (HR 2.30, 95% CI 1.06-4.98; p = 0.035). CRS occurred in 95.7% (grade ≥3, 2.1%) and ICANS in 5.3% (grade ≥3, 1.1%), with no difference by bridging intensity (p = 0.86 and p = 0.60, respectively). Intensive BT was associated with delayed platelet recovery >100 × 10⁹/L (p = 0.0096) and delayed neutrophil recovery >1.0 × 10⁹/L (p = 0.031). Grade ≥3 infections were similar across cycle groups (p = 0.29), including grade ≥3 viral infections (p = 0.12).

CONCLUSIONS:

Intensive cyclophosphamide-containing multi-agent BT (VTD-PACE/DCEP) was associated with delayed hematologic recovery but was not independently associated with inferior PFS after ide-cel when accounting for baseline disease aggressiveness. These findings suggest that intensive bridging may be considered for selected patients with aggressive RRMM requiring effective disease control prior to ide-cel infusion, with no statistically significant increase in CRS or ICANS.

2026-03-01·CANCER CELL

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma

Article

作者: Bach, Enrica ; Jentzsch, Madlen ; Herling, Marco ; Scheller, Lukas ; Kreuz, Markus ; Friedrich, Mirco ; Kuball, Jürgen ; Merz, Maximilian ; Metzeler, Klaus H ; Baber, Ronny ; Keramati, Farid ; Vucinic, Vladan ; Wiemers, Thomas ; Grahnert, Anja ; Platzbecker, Uwe ; Friedrich, Maik ; Fischer, Luise ; Seiffert, Sabine ; Reiche, Kristin ; Fandrei, David ; Hoffmann, Sandra ; Scolnick, Jonathan ; Franke, Georg-Nikolaus ; Alb, Miriam ; Sebestyen, Zsolt ; Herling, Carmen Diana ; Brazda, Peter ; Rade, Michael ; Weidner, Heike ; Köhl, Ulrike ; Boldt, Andreas ; Hudecek, Michael ; Born, Patrick ; Hofbauer, Lorenz C ; Wang, Song Yau ; Einsele, Hermann

Chimeric antigen receptor (CAR) T cell therapies targeting B cell maturation antigen (BCMA) are transforming treatment for relapsed or refractory multiple myeloma (RRMM). We analyze 61 RRMM patients receiving idecabtagene vicleucel (Ide-cel; n = 34) or ciltacabtagene autoleucel (Cilta-cel; n = 27) and find that Cilta-cel achieves higher complete response (CR) rates (78% vs. 38%) and longer progression-free survival. Using a longitudinal single-cell multi-omics atlas of 135 blood samples, we show that Cilta-cel induces expansion of CD4⁺ cytotoxic T cells associated with CR and immune-related toxicities, whereas non-CR CD8⁺ T cells display impaired effector programs. Among non-B cells, plasmacytoid dendritic cells (pDCs) show the highest BCMA expression and BCMA-targeted agents eradicate a blastic plasmacytoid dendritic cell neoplasm line, suggesting a novel therapeutic avenue for this disease. Greater reductions in soluble BCMA correlate with enhanced CAR T expansion and systemic inflammation. These findings reveal cellular mechanisms driving differential efficacy and toxicity of BCMA-directed immunotherapy.

845

项与艾基维仑赛相关的新闻（医药）

2026-04-01

·生物圈小智的备忘录

绝境翻盘！BCMA——多发性骨髓瘤的“救命靶点”，CAR-T时代的黄金王者

在血液肿瘤界，有一个堪称 “生命收割机” 的恶性肿瘤 —— 多发性骨髓瘤。它是发病率第二的血液肿瘤，目前仍无法彻底治愈，极易复发，很多患者一次次化疗，一次次耐药，最终陷入无药可用的绝境。而 BCMA 靶点的出现，极大改写了多发性骨髓瘤的治疗历史，把这个“难治之症”，拉进了慢病化管理、部分患者可实现长期缓解的时代。它不仅是多发性骨髓瘤的核心治疗靶点，更是细胞治疗领域最成熟、最成功的实体靶点之一，从 CAR-T 到 ADC，再到双抗，几乎所有创新药形式，都在它身上创造了奇迹。今天，我们就来聊聊，这个被称为 “血液肿瘤克星” 的 BCMA 靶点，到底有多厉害。 01 什么是BCMA靶点 BCMA的全称是 B 细胞成熟抗原，最大的特点，就是表达高度局限，主要长在 B 细胞和浆细胞谱系上，正常组织几乎不会广谱表达。需要注意的是，BCMA 并非肿瘤细胞独有，它确实也在部分正常浆细胞和成熟 B 细胞上表达，这也是靶向 BCMA 药物会导致低丙种球蛋白血症（体液免疫缺陷）这一常见副作用的原因。而多发性骨髓瘤的癌细胞，恰恰就是恶变的浆细胞，临床数据显示，约90%-95%的患者会表达BCMA，且表达水平存在异质性，部分患者（尤其是经过多次治疗后）可能出现BCMA低表达或阴性复发，这是耐药的重要机制之一。这意味着什么？BCMA 就是癌细胞身上极具特异性的 “专属通缉令”，是免疫系统精准打击癌细胞的完美坐标。靶向 BCMA 的药物，能精准找到所有高表达 BCMA 的骨髓瘤细胞，对它们展开毁灭性打击，而几乎不会误伤正常细胞，完美实现了 “高效低毒” 的精准治疗。也正是这个独一无二的优势，让 BCMA 成了多发性骨髓瘤治疗的 “天选靶点”，各种创新疗法都在它身上实现了突破，三大类相关药物更是各显神通，给患者带来了层层递进的治疗选择（注：ADC类部分药物目前处于特殊状态，详见下文说明）。 02 CAR-T细胞疗法第一类，也是最出圈的，就是 CAR-T 细胞疗法。简单来说，就是把患者自身的 T 细胞抽出来，在实验室里给它装上能精准识别 BCMA 的 “导航仪”，改造后的 CAR-T 细胞，回输到患者体内后，能精准找到所有骨髓瘤细胞，把它们全部清除，有望实现深度缓解和长期无进展生存。全球首款获批的 BCMA CAR-T 疗法，是百时美施贵宝与蓝鸟生物联合开发的 Abecma，它的出现，让多次复发耐药的晚期患者，依然能获得超高的缓解率。而国产药企在这个赛道表现突出，传奇生物的西达基奥仑赛确实是全球范围内疗效数据最突出的BCMA CAR-T之一，并在美国、欧盟、中国等地获批，堪称“领跑”；驯鹿生物的伊基奥仑赛、科济生物 / 华东医药的泽沃基奥仑赛，也相继在国内获批上市，属于国产自主创新的成功，让中国患者用上了在国际舞台上展现出强大竞争力的国产CAR-T疗法，无数复发耐药的患者，在这里获得了新生。 03 双特异性抗体第二类，是双特异性抗体。它就像一个 “双面胶”，一面牢牢粘住骨髓瘤细胞上的 BCMA，另一面粘住 T 细胞上的CD3，把抗癌警察和癌细胞强行拉到一起，让 T 细胞精准击杀癌细胞。和 CAR-T 相比，双抗是现成的药物，不用等待制备，皮下注射就能使用，价格也更亲民，完美填补了 CAR-T 疗法的空白。目前国内已有多款 BCMA/CD3 双抗获批上市：强生旗下杨森制药研发的特立妥单抗，是全球首款获批的 BCMA 双抗，开启了双抗治疗骨髓瘤的新时代；辉瑞研发的埃纳妥单抗（易瑞欧 ®），更是凭借17.2个月的中位无进展生存期，创下了同类产品在关键临床研究中的最长记录之一，2025 年在国内获批后，迅速成为了临床核心选择；再生元的塔奎妥单抗也相继入局，形成了三足鼎立的格局，给患者带来了更多选择。 04 ADC药物（抗体偶联药物）第三类，是 ADC 药物。它就像一枚精准制导的 “生物导弹”，抗体部分精准识别 BCMA，找到癌细胞后，直接释放搭载的化疗毒素，把癌细胞从里到外彻底炸死，还能同时激活免疫系统，实现双重杀伤。全球首款获批的 BCMA 靶向药，是葛兰素史克研发的 Blenrep（Belantamab mafodotin），作为全球首个 BCMA ADC 药物，它于2020年获得美国FDA加速批准，第一次给无药可用的晚期患者带来了新的治疗希望。但需要注意的是，2022年由于其确证性III期临床试验（DREAMM-3）未达到主要终点（未显示优于标准治疗方案），葛兰素史克已主动将该药从美国市场撤市。目前葛兰素史克正通过新的联合治疗方案（DREAMM-7、DREAMM-8）寻求重新上市，预计2025-2026年有望再次获批，这也体现了药物研发的曲折与进步。 05 BCMA靶点改写了多发性骨髓瘤治疗格局从 CAR-T 到双抗，再到 ADC，从末线挽救治疗到更早线的应用，BCMA 靶点用一己之力，极大改善了多发性骨髓瘤患者的预后，将患者中位生存期从过去的2-3年延长至8-10年以上，显著改写了疾病的治疗格局。而它的故事还远未结束，越来越多的创新疗法正在研发中...

细胞疗法免疫疗法抗体药物偶联物

2026-03-31

·allsci.com

Caribou’s off-the-shelf BCMA CAR-T receives RMAT designation for multiple myeloma

Caribou Biosciences, Inc. (Nasdaq: CRBU), headquartered in Berkeley, California, announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, an allogeneic anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, for relapsed or refractory multiple myeloma (r/r MM). The designation adds to existing FDA Fast Track and Orphan Drug designations already held by CB-011 for the same indication, and confers eligibility for rolling and priority review and accelerated approval pathways, contingent on meeting relevant criteria at each stage. The clinical data underpinning the RMAT decision derive from the ongoing CaMMouflage Phase I trial (NCT05722418), a multicenter, open-label, 3+3 dose-escalation study enrolling adults with r/r MM who have received three or more prior lines of therapy. As of a September 24, 2025 data cutoff, previously disclosed in November 2025, 48 patients had been treated across multiple dose levels and two lymphodepletion (LD) regimens. The 450×10⁶ CAR-T cell dose was selected as the recommended dose for expansion (RDE). Among the 12 BCMA-naïve patients treated, efficacy outcomes included a 92% (11/12) overall response rate (ORR), a ≥complete response (CR) rate of 75% (9/12), and minimal residual disease (MRD) negativity in 91% (10/11 evaluable) of patients. No cases of graft-versus-host disease, immune effector cell-associated enterocolitis, parkinsonism, or cranial nerve palsies were observed at any dose level. Treatment-emergent adverse events (TEAEs) occurring in ≥25% of patients treated under the selected LD regimen (N=35) included neutropenia (80%), anemia (60%), thrombocytopenia (49%), infections (49%), cytokine release syndrome (31%), and dizziness (31%). The CaMMouflage trial has now moved into dose expansion, enrolling both BCMA-naïve and BCMA-exposed cohorts at the 450×10⁶ cell dose with cyclophosphamide 500 mg/m² and fludarabine 30 mg/m² daily for three days as the selected LD regimen. Caribou has indicated that initial dose expansion data, along with longer follow-up from dose escalation, are expected in 2026. Research context According to an investigator quoted in Caribou’s announcement, only approximately one in ten patients with multiple myeloma in the United States receives CAR-T therapy, a figure attributed to wait times and manufacturing limitations inherent to autologous approaches. CB-011’s allogeneic design — using donor-derived cells manufactured in advance — is intended to circumvent these logistical barriers. The approved anti-BCMA CAR-T landscape in r/r MM currently includes two autologous products: idecabtagene vicleucel (ide-cel; Bristol Myers Squibb/2seventy bio) and ciltacabtagene autoleucel (cilta-cel; Janssen/Legend Biotech). Both carry FDA approvals in heavily pretreated r/r MM populations and have demonstrated deep response rates in their respective pivotal trials, but share the manufacturing constraints that Caribou’s off-the-shelf approach seeks to address. No allogeneic anti-BCMA CAR-T product has yet reached regulatory approval. CB-011’s engineering distinguishes it from both approved autologous products and other allogeneic programs in development. According to Caribou, CB-011 is constructed using a beta-2 microglobulin (B2M) knockout combined with insertion of a B2M–HLA-E fusion protein — an immune-cloaking strategy designed to reduce host-mediated rejection of the allogeneic cells. The company states this makes CB-011 the first allogeneic CAR-T in the clinic to deploy this specific combination. Unlike autologous products such as ide-cel and cilta-cel, which rely on patient-derived T cells and are subject to manufacturing variability tied to individual patient immune status, CB-011 is manufactured from donor cells and stored for immediate deployment. The absence of graft-versus-host disease at any dose level in the CaMMouflage trial to date is a relevant safety signal for an allogeneic construct, though the patient numbers remain small and longer follow-up is needed. The RMAT designation framework, established under the 21st Century Cures Act, applies to regenerative medicine therapies — including cell therapies — intended to treat serious conditions where preliminary clinical evidence indicates the potential to address unmet medical needs. The designation enables more intensive FDA engagement during development, including the possibility of rolling review submissions. For Caribou, the practical near-term implication is structured dialogue with the FDA on the clinical development path for CB-011, particularly as the program transitions from Phase I dose expansion toward a potential registrational strategy. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

细胞疗法免疫疗法临床结果孤儿药快速通道

2026-03-30

·Biotechnology

高效基因编辑技术：如何选择合适的细胞治疗产品以实现商业成功？

我应该开发什么细胞/基因治疗产品？ 🔬 决策一：疾病机制类型（最先判断——直接决定技术可行性）疾病是由单基因缺陷驱动的，还是多因素复杂疾病？这是决定基因治疗/细胞治疗是否适用的根本前提；单基因 = 靶点明确、机制清晰、FDA"Plausible Mechanism Framework"适用 ✅ 单基因遗传病（Monogenic） 🎯 基因治疗的理想适应症 — 一个突变、一个靶点、一次干预单基因病（SCD、β-地贫、血友病、SMA、遗传性视网膜病、免疫缺陷等）：病因明确，可直接纠正或补偿突变基因，临床终点与靶点直接关联 ✅ FDA 2025 新增"Plausible Mechanism Framework"——单基因病可凭机制合理性缩短临床开发周期，无需大规模 RCT 🏆已批准代表产品：Casgevy（SCD/β-地贫）、Zolgensma（SMA）、Luxturna（遗传性视网膜病）、Hemgenix（血友病B）、Lenmeldy（MLD）——均为单基因病 ⚠️ 获得性癌症 / 血液肿瘤 🩸 细胞免疫治疗领域 — 工程化免疫细胞直接杀伤肿瘤不是纠正单基因缺陷，而是赋予免疫细胞识别并消灭肿瘤细胞的能力；CAR-T/TIL适应症为血液肿瘤（B细胞淋巴瘤、AML、MM）及部分实体瘤 📌 Kymriah、Yescarta、Carvykti均为自体CAR-T，目前仍是血液肿瘤的临床金标准 🆕 自身免疫病（新兴） 🛡️ CAR-T "深度重置"免疫系统 — 2024–2025 最热点新方向 CAR-T靶向B细胞（CD19）可清除自身抗体源，用于难治性红斑狼疮、系统性硬化症、重症肌无力等；关键优势：自身免疫病无需CAR-T持久存活，一次清除B细胞池后机体自然重建耐受 ⭐ 持久性要求低 → 降低对自体CAR-T最大障碍之一；试验结果惊人（部分患者2+年无药缓解） ❌ 多基因 / 复杂疾病（糖尿病、心血管、阿尔茨海默病） ⚠️ 基因治疗技术路径极度困难，当前不推荐优先开发多基因驱动 + 环境因素交互，无单一靶点可纠正；风险-收益比差，FDA对复杂机制产品要求大型RCT 例外：单基因原因导致的常见病表型可尝试（如PCSK9单基因高胆固醇血症→ Inclisiran；NTLA-2001肝脏CRISPR编辑PCSK9）——但须证明单一靶点驱动的机制 📊 决策二：患者规模 × 商业可行性（最常被忽视的死亡陷阱）目标疾病的全球患者规模是多少？规模决定定价空间、投资回报周期与制造经济性；CGT的高制造成本意味着规模过小可导致"商业化死亡谷"——即使疗法有效也无法维持运营 🚨 超罕见（全球< 500 患者/年） ⚠️ 极度高风险 — 可能陷入"商业化死亡谷" 治疗费用必须极高（>$2–3M/剂）才能覆盖研发成本，但患者极少 → 总市场额<$5亿/年，无法支撑商业运营 📉 真实案例警示：Strimvelis（ADA-SCID）— 欧洲首个获批ex vivo基因疗法，医学上治愈率极高，但Orchard Therapeutics 2023年因商业原因撤出市场，放弃该产品。原因：超罕见患者数不足以支撑GMP制造成本。💡出路：①学术/慈善机构接管制造 ②平台型策略（同一工艺针对多种超罕见病，摊薄固定成本）③政府资助/非营利模式 ④FDA"N-of-1"个体化疗法框架（2025 Plausible Mechanism Draft） ✅ 罕见病（500–5,000 患者/年，符合Orphan Drug定义） 💊 CGT的最佳商业甜点区 — 高单价 + 监管激励 + 可控制造定价$500K–$3.5M/剂在罕见病有支付者接受度；FDA孤儿药资格（ODD）给予7年独占期、税收抵免、减免申请费；RMAT资格加速开发；临床开发周期短（单臂10–30患者可支持BLA） 📌 FDA 2024-2025：88%的新批准CGT产品具有ODD资格；孤儿药+RMAT双资格 = 开发速度最快路径推荐开发策略：IND到Ph1/2约$50–120M（自体HSC）或$30–80M（in vivo AAV/LNP）；孤儿药资格可减免FDA申请费~$4M；关键是选择有清晰自然病史数据的疾病——支持BLA的外部对照 ✅ 常见病/高发肿瘤（>10,000 患者/年） 🏭 需要工业化制造能力 — 规模决定单位成本高发患者量要求GMP产能可扩展；初期资本投入大（制造基地$200–500M），但规模化后单位成本可压缩；竞争格局更激烈，需差异化定位 ⚠️ 重要：大规模RCT是必须的，临床成本是罕见病的5–10倍 ⚠️制造经济学关键：自体CAR-T成本难以大幅压缩（中央制造 + 个体化 + 物流），边界价格$400K–$700K/次已接近支付者容忍上限；降低成本的两条路径：①同种异体/通用型产品（但临床疗效尚未追上自体）②自动化/去中心化制造（点对点/床边制造） 🧪 决策三：什么产品形式最适合这个疾病？疾病的细胞类型与靶器官是什么？是否需要精准基因纠正？靶细胞可及性 + 编辑工具货物大小 + 是否需要整合 → 共同决定产品形式 🩸 造血系统疾病（SCD / β-地贫 / 原发性免疫缺陷） → 自体 HSC 编辑（ex vivo）从骨髓/外周血动员采集CD34⁺ HSPCs → 电穿孔RNP（NHEJ）或mRNA（碱基编辑）或RNP+AAV6（HDR）→ 回输 + 清髓预处理代表：Casgevy（CRISPR/RNP靶向BCL11A，无供体DNA）、Lyfgenia（LV转入βT87Q-globin） ⏱️ 开发周期：IND到BLA约7–12年 | 💰 资本：$100–300M Phase 1 to approval ⚠️自体HSC的核心局限：每位患者个体化制造（中央GMP工厂 → 患者 → 回输）；Casgevy定价$2.2M（SCD）、$3.1M（β-地贫），支付者覆盖率挑战大。未来方向：in vivo LNP递送编辑工具直接编辑骨髓HSPCs，绕过ex vivo流程（正在研究中） 🩺 血液肿瘤 CAR-T（B细胞淋巴瘤/MM/T-ALL） → 自体 CAR-T（当前金标准）+ 探索下一代策略自体T细胞采集 → LV/γ-RV稳定整合CAR → 扩增 → 回输；已有6个FDA批准产品（Kymriah、Yescarta、Breyanzi、Abecma、Carvykti、Aucatzyl）当前现状：① 尚无异体CAR-T获FDA批准 ② 异体CAR-T在业内处于"核寒冬"（Fierce Biotech 2025）——临床数据未能追上自体CAR-T疗效 ③ CAR-NK虽然无GvHD风险，但细胞内在信号弱、体内持久性差（NK细胞寿命短），同样无FDA批准产品💡新兴替代方向（更有前景）：①in vivo CAR-T（LNP/AAV直接体内编程T细胞，Capstan/Sana等）—— 消灭ex vivo制造环节 ② iPSC来源CAR-T/NK（Fate Therapeutics）—— 可再生、可标准化，仍在临床早期 ③ 下一代自体CAR（双CAR、逻辑门控CAR）提升疗效 🆕 自身免疫病（CAR-T 新赛道） → 自体 CAR-T 靶向 CD19（清除 B 细胞池）与肿瘤适应症关键不同：无需长期CAR-T持久性——一次B细胞清除后，宿主免疫系统自然重建耐受，因此ex vivo制造缺陷影响小；反应率和持续缓解时间令人惊叹（如Thomas Fürst团队SLE数据） ⭐ 商业逻辑更优：适应症患者更多（SLE/SSc/重症肌无力合计>10万/年）、制造需求更低、竞争对手少 🏥 肝脏单基因病（血友病 / PCSK9 / TTR 淀粉样变） → in vivo 递送（LNP-mRNA 或 AAV8/9）肝脏是in vivo基因治疗效率最高的靶器官；两条平行路径：①AAV8/9：一次性长效蛋白表达（Hemgenix $3.5M；Roctavian血友病A）②LNP+CRISPR：NTLA-2001（TTR永久编辑）、PCSK9敲减——单次给药，无AAV免疫原性问题 💰 in vivo制造成本远低于ex vivo；批量生产→储存→配送 🎯 眼 / 肌肉 / CNS 单基因病 → AAV 局部给药 — 无需大规模制造 Luxturna（AAV2视网膜下注射）、Zolgensma（AAV9 SMA）、Elevidys（AAV DMD）；局部给药剂量小、全身暴露低 ⚠️ 血清型匹配：眼→AAV2/5/8；肌肉→AAV9/1；CNS→AAV9/rh10 🏭 决策四：制造策略 — 自体 vs 同种异体 vs in vivo 选择哪种制造模式？（商业化的核心瓶颈）制造模式决定每剂成本、准入及时性、规模可行性；是CGT商业化最大挑战 ✅ 自体产品（Autologous）— 当前临床有效性金标准患者专属制造 → 最高疗效，但成本/周期是最大制约每剂定价$400K–$3.5M（CAR-T约$400–700K，基因编辑$2–3.5M）；制造周期2–4周；GMP中央工厂→物流复杂；Kymriah历史制造失败率9% 降本方向：自动化封闭系统（Lonza Cocoon、Ori Biotech）、去中心化床边制造 ⚠️ 同种异体产品（Allogeneic）— 2025年仍无FDA批准产品供者细胞批量制造 → "现货"供应，但持久性与疗效差距尚未解决 Roche/Poseida（$1.5B收购，2024）、CTX110（Caribou）、FT596（CAR-NK）均在临床中；最大挑战：体内持久性差于自体，肿瘤领域疗效数据不及自体CAR-T 何时allogeneic更有优势：① 自身免疫病（无需持久性）② 患者细胞质量差无法制造自体产品 ③ 需要"即刻给药"的急性适应症💡iPSC来源的allo产品（iPSC-CAR-T/CAR-NK）是最可再生的方向——一个细胞库可治疗无数患者，但iPSC分化效率和T细胞功能仍是技术瓶颈 🆕 in vivo 产品（LNP / AAV）— 最低制造复杂度，最高可及性潜力直接向患者体内递送 → 消灭ex vivo全部制造环节无需采集细胞、无需中央制造工厂、可批量生产药物→储存→配送；成本结构接近生物制剂，有望大幅降低每剂成本新兴in vivo CAR-T（LNP/AAV递送CAR构建体，体内编程患者T细胞）正在突破ex vivo最后屏障 ⭐ CGT商业化"终极形态"：批量制造 + 全球配送 + 无个体化制造风险 ⚠️当前局限：in vivo LNP主要靶向肝脏（被动富集），其他组织靶向效率待提升；in vivo CAR-T仍在临床前/Phase 1阶段；AAV单次给药后无法重复（NAb），分裂细胞中附加体稀释 📊 四类 CGT 产品商业路径速查对比

免疫疗法细胞疗法基因疗法临床研究

100 项与艾基维仑赛相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11556	-	L01XX	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
难治性多发性骨髓瘤	日本	Bristol-Myers Squibb KK	2022-04-01
复发性多发性骨髓瘤	日本	Bristol-Myers Squibb KK	2022-04-01
多发性骨髓瘤	美国	Celgene Corp.	2021-03-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
BCMA阳性多发性骨髓瘤	临床1期	美国	Celgene Corp.	2015-12-22
BCMA阳性多发性骨髓瘤	临床1期	美国	bluebird bio, Inc.	2015-12-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Tandem Meetings ASTCT and CIBMTR2026	N/A	复发性多发性骨髓瘤	813	Idecabtagene Vicleucel (Non-Hispanic White)	鑰獵鏇窪憲製衊艱積艱(壓膚遞襯糧廠夢襯壓廠) = 願網獵範範窪醖醖淵繭襯製鏇齋鹽築網選廠糧 (鏇築醖獵餘鑰齋積觸壓 ) 更多	不佳	2026-02-04
				Idecabtagene Vicleucel (Non-Hispanic Black)	鑰獵鏇窪憲製衊艱積艱(壓膚遞襯糧廠夢襯壓廠) = 齋構衊廠膚壓糧製鑰衊襯製鏇齋鹽築網選廠糧 (鏇築醖獵餘鑰齋積觸壓 ) 更多
Tandem Meetings ASTCT and CIBMTR2026	N/A	复发性多发性骨髓瘤	821	Idecabtagene Vicleucel (Clinically High-Risk Patients)	憲餘膚觸築選積艱襯觸(簾鹹艱糧壓鹹簾範繭範) = 簾餘衊夢糧餘願範築廠衊製齋膚淵簾積鹹糧觸 (鑰衊淵淵鏇構選積鬱網 ) 更多	不佳	2026-02-04
				Idecabtagene Vicleucel (Genetically High-Risk Patients)	淵夢淵鑰夢襯顧鹽構願(繭範願艱鏇繭製簾廠艱) = 糧壓鹹製構獵鏇製衊顧齋窪願蓋憲鬱獵願壓窪 (衊範鏇顧顧窪壓窪憲鑰 ) 更多
Tandem Meetings ASTCT and CIBMTR2026	N/A	难治性多发性骨髓瘤	807	Idecabtagene Vicleucel	襯襯選壓築窪膚築膚鹽(廠蓋艱艱衊鬱淵淵鹹衊) = 餘選製網餘鬱鑰願蓋願繭遞獵壓製遞製窪觸繭 (夢夢鏇膚鬱鏇夢鹹餘觸 ) 更多	积极	2026-02-04
Tandem Meetings ASTCT and CIBMTR2026	N/A	难治性多发性骨髓瘤	813	Received prior BCMA-directed therapy	壓壓壓淵鏇構壓繭觸遞(構鏇夢遞憲襯範蓋遞艱) = 獵選蓋窪積膚遞膚衊鹹膚夢遞壓艱願醖糧窪鏇 (遞製簾餘夢鑰顧糧糧範 ) 更多	不佳	2026-02-04
				Not received prior BCMA-directed therapy	壓壓壓淵鏇構壓繭觸遞(構鏇夢遞憲襯範蓋遞艱) = 鑰壓鹽衊窪糧壓範衊構膚夢遞壓艱願醖糧窪鏇 (遞製簾餘夢鑰顧糧糧範 ) 更多
NCT03651128 (KarMMa-3, Tandem Meetings ASTCT and CIBMTR2026)	临床3期	多发性骨髓瘤	302	Idecabtagene vicleucel (ide-cel)	鏇廠鏇構餘窪構繭壓夢(鏇構鹹餘鬱觸餘鑰廠齋) = 簾願鏇選艱遞繭積憲襯願蓋壓鬱廠齋繭齋繭壓 (築構願網顧齋衊製積淵 ) 更多	积极	2026-02-04
				Standard Regimens (SR)	鏇廠鏇構餘窪構繭壓夢(鏇構鹹餘鬱觸餘鑰廠齋) = 構鏇鹽積憲選廠範願廠願蓋壓鬱廠齋繭齋繭壓 (築構願網顧齋衊製積淵 ) 更多
NCT03651128 (KarMMa-3, Tandem Meetings ASTCT and CIBMTR2026)	临床3期	复发性多发性骨髓瘤	386	Idecabtagene vicleucel (ide-cel) (patients aged <70 y)	鑰齋鏇鹽願膚餘獵構艱(獵膚鏇築願蓋鹽廠製鹽) = 齋構夢顧衊選簾鏇顧築範膚窪繭遞餘製繭選鹹 (願簾觸餘艱網願網鹹襯, 62.4 ~ 75.1) 更多	积极	2026-02-04
				Standard regimens (patients aged <70 y)	鑰齋鏇鹽願膚餘獵構艱(獵膚鏇築願蓋鹽廠製鹽) = 構夢範簾淵憲鬱膚淵顧範膚窪繭遞餘製繭選鹹 (願簾觸餘艱網願網鹹襯, 31.5 ~ 50.4) 更多
Tandem Meetings ASTCT and CIBMTR2026	N/A	多发性骨髓瘤	90	ABECMA	鹹鏇鹽願糧糧壓齋鏇蓋(簾窪艱築鑰構構願襯願) = 齋積顧鏇廠鬱繭網鏇遞夢襯鏇鬱積淵窪淵網餘 (顧糧製鏇積鑰簾艱窪蓋 )	积极	2026-02-04
Tandem Meetings ASTCT and CIBMTR2026	N/A	多发性骨髓瘤	938	Idecabtagene vicleucel (ide-cel)	蓋淵鑰壓鹹壓鹽鹹鏇鑰(築顧廠淵鑰膚鹹廠餘淵): OR = 0.71 (95.0% CI, 0.55 ~ 0.92), P-Value = 0.009 更多	积极	2026-02-04
				Ciltacabtagene autoleucel (cilta-cel)
Tandem Meetings ASTCT and CIBMTR2026	N/A	多发性骨髓瘤 \| 非霍奇金淋巴瘤	3	Lisocabtagene maraleucel	艱餘觸夢蓋廠襯構壓窪(遞鹽襯憲選選簾觸築鏇) = No ICU transfers for cytokine release syndrome or immune-effector cell associated neurotoxicity syndrome occurred. Readmissions after discharge were not seen. 醖餘願憲簾獵膚齋膚選 (鬱簾鬱鬱鬱顧繭製衊蓋 ) 更多	积极	2026-02-04
				Idecabtagene vicleucel
NCT04181827 \| NCT03548207 \| NCT03651128 (CARTITUDE-4, Pubmed \| Adv Ther)	临床3期	复发性多发性骨髓瘤	221	Cilta-cel	鏇獵襯願願繭鹽襯鹹獵(糧廠遞壓廠觸構構觸蓋): RR = 1.22 (95.0% CI, 1.08 ~ 1.38), P-Value = 0.0126 更多	优效	2026-02-02
				Ide-cel